Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Depsipeptides × 1 year × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡